Skip to main content
SpringerLink
Log in

Overview of Idiopathic Pulmonary Fibrosis

  • Chapter
  • First Online:
Guide to Clinical Management of Idiopathic Pulmonary Fibrosis

  • 648 Accesses

Abstract

Interstitial lung diseases (ILDs) represent a broad category of diseases affecting the interstitium of the lung in a diffuse fashion. Idiopathic pulmonary fibrosis (IPF) is a distinct subtype and one of the most common forms of ILD. It is a chronic fibrosing condition that is limited to the lungs, tends to be progressive in nature, and results in significant morbidity and mortality. IPF needs to be differentiated from the many other causes ILDs. Table 1.1 categorizes all the ILDs by a simple mnemonic of five ‘I’s, a ‘C’, and an ‘N’ [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wallis A, Spinks K. The diagnosis and management of interstitial lung diseases. BMJ. 2015;350:h2072.

    Article  PubMed  Google Scholar 

  2. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.

    Article  PubMed  Google Scholar 

  3. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733–48.

    Article  PubMed  Google Scholar 

  4. Hunninghake GW, Gadek JE, Kawanami O, Ferrans VJ, Crystal RG. Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage. Am J Pathol. 1979;97:149–206.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Reynolds HY, Fulmer JD, Kazmierowski JA, Roberts WC, Frank MM, Crystal RG. Analysis of cellular and protein content of broncho-alveolar lavage fluid from patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. J Clin Invest. 1977;59:165–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Weinberger SE, Kelman JA, Elson NA, et al. Bronchoalveolar lavage in interstitial lung disease. Ann Intern Med. 1978;89:459–66.

    Article  CAS  PubMed  Google Scholar 

  7. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King Jr TE, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366:1968–77.

    Article  Google Scholar 

  8. King CS, Nathan SD. Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2015;21:479–89.

    Article  CAS  PubMed  Google Scholar 

  9. Karimi-Shah BA, Chowdhury BA. Forced vital capacity in idiopathic pulmonary fibrosis–FDA review of pirfenidone and nintedanib. N Engl J Med. 2015;372:1189–91.

    Article  PubMed  Google Scholar 

  10. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11. Lancet Respir Med. 2014;2:566–72.

    Article  PubMed  Google Scholar 

  11. Ley B, Collard HR, King Jr TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–40.

    Article  PubMed  Google Scholar 

  12. Alakhras M, Decker PA, Nadrous HF, Collazo-Clavell M, Ryu JH. Body mass index and mortality in patients with idiopathic pulmonary fibrosis. Chest. 2007;131:1448–53.

    Article  PubMed  Google Scholar 

  13. Antoniou KM, Hansell DM, Rubens MB, et al. Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am J Respir Crit Care Med. 2008;177:190–4.

    Article  PubMed  Google Scholar 

  14. Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997;155:242–8.

    Article  CAS  PubMed  Google Scholar 

  15. Miyake Y, Sasaki S, Yokoyama T, et al. Occupational and environmental factors and idiopathic pulmonary fibrosis in Japan. Ann Occup Hyg. 2005;49:259–65.

    Article  PubMed  Google Scholar 

  16. Lawson WE, Grant SW, Ambrosini V, et al. Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax. 2004;59:977–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Garcia CK. Idiopathic pulmonary fibrosis: update on genetic discoveries. Proc Am Thorac Soc. 2011;8:158–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Chibbar R, Shih F, Baga M, et al. Nonspecific interstitial pneumonia and usual interstitial pneumonia with mutation in surfactant protein C in familial pulmonary fibrosis. Mod Pathol. 2004;17:973–80.

    Article  CAS  PubMed  Google Scholar 

  19. Guillot L, Epaud R, Thouvenin G, et al. New surfactant protein C gene mutations associated with diffuse lung disease. J Med Genet. 2009;46:490–4.

    Article  CAS  PubMed  Google Scholar 

  20. Maitra M, Wang Y, Gerard RD, Mendelson CR, Garcia CK. Surfactant protein A2 mutations associated with pulmonary fibrosis lead to protein instability and endoplasmic reticulum stress. J Biol Chem. 2010;285:22103–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Nogee LM, Dunbar 3rd AE, Wert SE, Askin F, Hamvas A, Whitsett JA. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med. 2001;344:573–9.

    Article  CAS  PubMed  Google Scholar 

  22. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364:1503–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Thomas AQ, Lane K, Phillips 3rd J, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med. 2002;165:1322–8.

    Article  PubMed  Google Scholar 

  24. van Moorsel CH, van Oosterhout MF, Barlo NP, et al. Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a dutch cohort. Am J Respir Crit Care Med. 2010;182:1419–25.

    Article  PubMed  Google Scholar 

  25. Verleden GM, du Bois RM, Bouros D, et al. Genetic predisposition and pathogenetic mechanisms of interstitial lung diseases of unknown origin. Eur Respir J Suppl. 2001;32:17–29s.

    Google Scholar 

  26. Wang Y, Kuan PJ, Xing C, et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet. 2009;84:52–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Zhang Y, Noth I, Garcia JG, Kaminski N. A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. N Engl J Med. 2011;364:1576–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Ono S, Tanaka T, Ishida M. Surfactant protein C G100S mutation causes familial pulmonary fibrosis in Japanese kindred. Eur Respir J. 2011;38:861–9.

    Article  CAS  PubMed  Google Scholar 

  29. Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med. 2007;356:1317–26.

    Article  CAS  PubMed  Google Scholar 

  30. Lawson WE, Loyd JE, Degryse AL. Genetics in pulmonary fibrosis–familial cases provide clues to the pathogenesis of idiopathic pulmonary fibrosis. Am J Med Sci. 2011;341:439–43.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Mathai SK, Yang IV, Schwarz MI, Schwartz DA. Incorporating genetics into the identification and treatment of idiopathic pulmonary fibrosis. BMC Med. 2015;13:191.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA. 2013;309:2232–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Diaz de Leon A, Cronkhite JT, Yilmaz C, et al. Subclinical lung disease, macrocytosis, and premature graying in kindreds with telomerase (TERT) mutations. Chest. 2011;140:753–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A. 2007;104:7552–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Diaz de Leon A, Cronkhite JT, Katzenstein AL, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One. 2010;5:e10680.

    Google Scholar 

  36. Young LR, Nogee LM, Barnett B, Panos RJ, Colby TV, Deutsch GH. Usual interstitial pneumonia in an adolescent with ABCA3 mutations. Chest. 2008;134:192–5.

    Article  CAS  PubMed  Google Scholar 

  37. Sgalla G, Biffi A, Richeldi L. Idiopathic pulmonary fibrosis: diagnosis, epidemiology and natural history. Respirology. 2015. doi:10.1111/resp.12683. [Epub ahead of print].

    PubMed  Google Scholar 

  38. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176:636–43.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest. 2011;140:221–9.

    Article  PubMed  Google Scholar 

  40. King C, Nathan SD. Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases. Curr Opin Pulm Med. 2013;19:466–73.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Inova Fairfax Medical Campus, Falls Church, Virginia, USA

    Steven D Nathan, A Whitney Brown & Christopher S King

Authors
  1. Steven D Nathan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Whitney Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christopher S King
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Nathan, S.D., Brown, A.W., King, C.S. (2016). Overview of Idiopathic Pulmonary Fibrosis. In: Guide to Clinical Management of Idiopathic Pulmonary Fibrosis. Adis, Cham. https://doi.org/10.1007/978-3-319-32794-5_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-32794-5_1

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-32792-1

  • Online ISBN: 978-3-319-32794-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation